Cancer Tumor Profiling Market: Technology Overview & Outlook to 2024 by Worldwide Market Size, Key Vendors, Growth Rate, Drivers, Volume & Forecast Report

Global Cancer Tumor Profiling Market accounted to USD 25,318 million in 2016 growing at a CAGR of 18.3% during the forecast period of 2017 to 2024.

Cancer is proving the most fatal disease nowadays, therefor profiling cancer is in the great demand. The potential of cancer profiling is extended from common cancers such as lymphoma and breast cancer to molecular profiling of lung cancer, prostate cancer and acute leukemia. Cancer profiling plays vital role in the diagnosis and understanding of the cancer tumors to help physicians to take appropriate therapeutic decisions.

Get Free Sample Report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-tumor-profiling-market

The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

This Report Consists of Below Pages:

• No of pages: 350
• No of Figures: 60
• No of Tables: 220

Major Market Drivers and Restraints:

• Technological advancements for identifying the cancer tumors.
• Increasing the cancer incidences.
• Increase in demand for next generation sequencing technique in cancer profiling.
• Lack of Skilled Professionals and Infrastructure
• Growth in demand of personalized medicines
• Increase in the use of biomarkers in tumor profiling.
• Availability of Funding for Cancer Research

Inquiry Before buying: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-tumor-profiling-market

Market Segmentation:
The global cancer tumor profiling market is segmented by technology into next-generation sequencing, polymerase chain reaction, immunohistochemistry, in situ hybridization and microarray.In Situ Hybridization is further segmented into Fluorescence in Situ hybridization and chromogenic in situ hybridization.

By Technique the market is segmented in genomics, proteomics, epigenetics and metabolomics.

By Application the market is segmented into personalized medicine, diagnostics, biomarker discovery, prognostics and research applications.

On the basis of geography, global cancer tumor profiling market report covers data points for 28 countries across multiple geographies such as
North America &
South America,
Europe,
Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, andBrazil among others. In 2017, North America is expected to dominate the market.

Any Query talk to Analyst: http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-cancer-tumor-profiling-market

Table Of Content:

1. INTRODUCTION

1.1 OVERVIEW OF THE GLOBAL CANCER TUMOR PROFILING MARKET
1.2 CURRENCY AND PRICING
1.3 LIMITATION
1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL CANCER TUMOR PROFILING MARKET

2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CANCER TUMOR PROFILING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING INCIDENCES OF CANCER PATIENT
3.1.2 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCH
3.1.3 RISING GOVERNMENT INITIATIVES AND AVAILABILITY OF FUNDING FOR CANCER RESEARCH
3.1.4 INCREASE IN THE USE OF BIOMARKERS IN TUMOR PROFILING

3.2 RESTRAINTS

3.2.1 LACK OF OF WELL-TRAINED AND EXPERIENCED PROFESSIONALS
3.2.2 HIGH MONETARY INVESTMENTS AND LOW BENEFIT RATIO FOR BIOMARKERS AND BIOSIMILAR
3.3 OPPORTUNITIES
3.3.1 RISING DEMAND FOR PERSONALIZED MEDICINE
3.3.2 INNOVATION OF POINT-OF-CARE & MINIATURIZED DIAGNOSTIC DEVICES
3.4 CHALLENGES
3.4.1 STRINGENT REGULATORY PROCEDURE AND REIMBURSEMENT POLICIES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL CANCER TUMOR PROFILING MARKET, BY TECHNOLOGY

6.1 OVERVIEW
6.2 NEXT-GENERATION SEQUENCING
6.3 QUANTITATIVE POLYMERASE CHAIN REACTION
6.4 IMMUNOHISTOCHEMISTRY
6.5 IN SITU HYBRIDIZATION
6.5.1 FLUORESCENCE IN SITU HYBRIDIZATION
6.5.2 CHROMOGENIC IN SITU HYBRIDIZATION
6.6 MICROARRAY
6.7 FRAGMENT ANALYSIS

7 GLOBAL CANCER TUMOR PROFILING MARKET, BY TECHNIQUE

7.1 OVERVIEW
7.2 GENOMICS
7.3 PROTEOMICS
7.4 EPIGENETICS
7.5 METABOLOMICS

8 GLOBAL CANCER TUMOR PROFILING MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 PERSONALIZED MEDICINE
8.3 DIAGNOSTICS
8.4 BIOMARKER DISCOVERY
8.5 PROGNOSTICS
8.6 RESEARCH APPLICATIONS

9 GLOBAL CANCER TUMOR PROFILING MARKET, BY COUNTRY

9.1 GLOBAL CANCER TUMOR PROFILING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

9.1.1 NORTH AMERICA

9.1.1.1 U.S.
9.1.1.2 CANADA
9.1.1.3 MEXICO

9.1.2 EUROPE

9.1.2.1. GERMANY
9.1.2.2 FRANCE
9.1.2.3 U.K.
9.1.2.4 ITALY
9.1.2.5 SPAIN
9.1.2.6 RUSSIA
9.1.2.7 TURKEY
9.1.2.8 BELGIUM
9.1.2.9 NETHERLANDS
9.1.2.10 SWITZERLAND
9.1.2.11 REST OF EUROPE

9.1.3 ASIA-PACIFIC (APAC)

9.1.3.1 JAPAN
9.1.3.2 CHINA
9.1.3.3 SOUTH KOREA
9.1.3.4 INDIA
9.1.3.5 AUSTRALIA
9.1.3.6 SINGAPORE
9.1.3.7 THAILAND
9.1.3.8 MALAYSIA
9.1.3.9 INDONESIA
9.1.3.10 PHILIPPINES
9.1.3.11 REST OF APAC

9.1.4 SOUTH AMERICA

9.1.4.1 BRAZIL
9.1.4.2 REST OF LATIN AMERICA

9.1.5 MIDDLE EAST AND AFRICA

9.1.5.1 SAUDI ARABIA
9.1.5.2 SOUTH AFRICA
9.1.5.3 REST OF MIDDLE EAST AND AFRICA
9.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

10 GLOBAL CANCER TUMOR PROFILING MARKET: COMPETITIVE LANDSCAPE

10.1. GLOBAL CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.2. NORTH AMERICA CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.4. APAC CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.5. MERGERS & ACQUISITIONS
10.6. NEW PRODUCT DEVELOPMENT & APPROVALS
10.7. EXPANSIONS
10.8. REGULATORY CHANGES
10.9. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

11 GLOBAL CANCER TUMOR PROFILING MARKET, COMPANY PROFILES

11.1 ILLUMINA, INC.

11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL ANALYSIS
11.1.3 PRODUCT MATRIX
11.1.4 RECENT DEVELOPMENTS
11.1.5 DATABRIDGE ANALYSIS

11.2 QIAGEN

11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL ANALYSIS
11.2.3 PRODUCT MATRIX
11.2.4 RECENT DEVELOPMENTS
11.2.5 DATABRIDGE ANALYSIS

11.3 F. HOFFMANN-LA ROCHE LTD

11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL ANALYSIS
11.3.3 PRODUCT MATRIX
11..3.4 RECENT DEVELOPMENTS
11.3.5 DATABRIDGE ANALYSIS

11.4 HTG MOLECULAR DIAGNOSTICS, INC.

11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL ANALYSIS
11.4.3 PRODUCT MATRIX
11.4.4 RECENT DEVELOPMENTS
11.4.5 DATABRIDGE ANALYSIS

11.5 GENOMIC HEALTH

11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL ANALYSIS
11.5.3 PRODUCT MATRIX
11.5.4 RECENT DEVELOPMENTS
11.5.5 DATABRIDGE ANALYSIS

11.6 CARIS LIFE SCIENCES

11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL ANALYSIS
11.6.3 PRODUCT MATRIX
11.6.4 RECENT DEVELOPMENTS
11.6.5 DATABRIDGE ANALYSIS

11.7 HELOMICS CORP.

11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL ANALYSIS
11.7.3 PRODUCT MATRIX
11.7.4 RECENT DEVELOPMENTS
11.7.5 DATABRIDGE ANALYSIS

11.8 NANOSTRING TECHNOLOGIES, INC.

11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL ANALYSIS
11.8.3 PRODUCT MATRIX
11.8.4 RECENT DEVELOPMENTS
11.8.5 DATABRIDGE ANALYSIS

11.9 OXFORD GENE TECHNOLOGY

11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL ANALYSIS
11.9.3 PRODUCT MATRIX
11.9.4 RECENT DEVELOPMENTS
11.9.5 DATABRIDGE ANALYSIS

11.10 ABBOTT

11.10.1 COMPANY OVERVIEW
11. 10.2 FINANCIAL ANALYSIS
11. 10.3 PRODUCT MATRIX
11.10.4 RECENT DEVELOPMENTS
11.10.5 DATABRIDGE ANALYSIS

11.11 HELOMICS CORP.

11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL ANALYSIS
11.11.3 PRODUCT MATRIX
11.11.4 RECENT DEVELOPMENTS
11.11.5 DATABRIDGE ANALYSIS

11.12 GENSCRIPT

11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL ANALYSIS
11.12.3 PRODUCT MATRIX
11.12.4 RECENT DEVELOPMENTS
11.12.5 DATABRIDGE ANALYSIS

11.13 RIBOMED

11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL ANALYSIS
11.13.3 PRODUCT MATRIX
11.13.4 RECENT DEVELOPMENTS
11.13.5 DATABRIDGE ANALYSIS

11.14 HOLOGIC, INC.

11.14.1 COMPANY OVERVIEW
11.14.2 FINANCIAL ANALYSIS
11.14.3 PRODUCT MATRIX
11.14.4 RECENT DEVELOPMENTS
11.14.5 DATABRIDGE ANALYSIS

11.15 BOREAL GENOMICS INC.

11.15.1 COMPANY OVERVIEW
11.15.2 FINANCIAL ANALYSIS
11.15.3 PRODUCT MATRIX
11.15.4 RECENT DEVELOPMENTS
11.15.5 DATABRIDGE ANALYSIS

11.16 PERTHERA, INC.

11.16.1 COMPANY OVERVIEW
11.16.2 FINANCIAL ANALYSIS
11.16.3 PRODUCT MATRIX
11.16.4 RECENT DEVELOPMENTS
11.16.5 DATABRIDGE ANALYSIS

11.17 NEOGENOMICS LABORATORIES, INC.

11.17.1 COMPANY OVERVIEW
11.17.2 FINANCIAL ANALYSIS
11.17.3 PRODUCT MATRIX
11.17.4 RECENT DEVELOPMENTS
11.17.5 DATABRIDGE ANALYSIS

12 APPENDIX

13 ABOUT DATA BRIDGE MARKET RESEARCH

If you have any special requirements, please let us know and we will offer you the report as you want

Access Full TOC@ http://databridgemarketresearch.com/toc/?dbmr=global-cancer-tumor-profiling-market

Competitive Analysis:

The global cancer tumor profiling market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global cancer tumor profiling market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors:

Some of the major players operating in global cancer tumor profiling marketareIllumina, Inc., Qiagen N.V., F. Hoffmann-La Roche AG, NeoGenomics Laboratories, Inc., HTG Molecular Diagnostics, Inc., Genomic Health Inc. , Caris Life Sciences, Helomics Corp., NanoString Technologies, Inc., Oxford Gene Technology, Abbott, BD, Hologic, Inc., Siemens Medical Solutions USA, Inc., Personal Genome Diagnostics, Inc., FOUNDATION MEDICINE, INC., Contextual Genomics, AGENDIA, Perthera, Inc., ApoCell, GenScript, Ribomed, Boreal Genomics Inc., Biotheranostics and Proteome Sciences among others.

Access Full Report@ http://databridgemarketresearch.com/reports/global-cancer-tumor-profiling-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com

This release was published on openPR.